FAST NEWS: JW Therapeutics’ revenue soars on growing lymphoma drug sales
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Wednesday its revenue surged 373% to 146 million yuan ($21.2 million) last year, while its non-GAAP net loss narrowed…
Recent Articles
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
-
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK 688428.SHG
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
